🔗 Share this article

As the US continues making unprecedented adjustments to its vaccination guidelines, a particular individual has surfaced somewhat surprisingly: Tracy Beth Høeg, an American of Danish descent physician and epidemiologist who rose to prominence by casting doubt on COVID-19 vaccines in the global health crisis and has focused upon alleged deaths following COVID-19 vaccination in her brief time at the US Food and Drug Administration (FDA).

Planned Overhauls to Pediatric Vaccine Program

Public health authorities planned to announce radical changes to the childhood vaccine schedule in December, bringing the US with the Danish vaccine program, sources say – a substantial departure that would put the US out of step with a large portion of the international standard with little proof for improved outcomes. The announcement has been postponed until the next year.

In place of Vinay Prasad, Tracy Beth Høeg is scheduled to address the audience at the gathering. She was newly appointed interim head of the FDA’s drug evaluation center, the fifth individual to head the division this calendar year.

A New Direction at the FDA

The acting appointment may indicate a closer partnership between the pharmaceutical and vaccine centers as Dr. Høeg and Dr. Prasad consolidate power at the agency – and it signals a increased emphasis upon dismantling previously authorized vaccines at the FDA.

Dr. Høeg has often pushed for discontinuing certain pediatric vaccine recommendations in the US in order to be more like the Danish model, a country with nationalized medicine and a citizenry roughly the population of the state of Wisconsin.

To date comments, she has continued to focus on vaccines – usually the responsibility of Dr. Prasad, director of the FDA’s Center for Biologics Evaluation and Research (CBER) – instead of drug regulation.

Doubts Over Expertise

Dr. Høeg has no apparent background in drug development, oversight or leadership, which has been typical for past heads of the biologics center. She has worked at the FDA as a top consultant to the FDA chief and the vaccine center since March.

“It seems she lacks to have the necessary background” for leading the CDER, remarked a neurologist and psychiatrist. “She has not conducted a randomized controlled trial. She lacks experience in managing a large organization. She lacks background in industry regulation.”

Past commissioners of the center would “understand regulatory frameworks and the underlying principles of medication creation”, commented a former acting FDA commissioner. “Frankly, she lacks the kind of background that prior appointees who ran the center have had.”

The drug center has an vast range of responsibilities at the FDA, Woodcock pointed out.

“Many people just focuses on the innovative therapies, but the off-patent medication office clears numerous off-brand pharmaceuticals. There is also a biosimilars program, non-prescription drug unit and other areas, and each of these have to be supervised,” Woodcock said. “The responsibility you overlook, that is precisely what that I always told people is going to bite you.”

Additionally, a significant administrative aspect to the role, which manages more than 5,000 staff members. “It’s a massive management job, if you do it right,” she concluded.

Response and Controversial Programs

In response to questions about Høeg’s fitness for the role and whether this selection indicates greater collaboration among regulatory chiefs on immunizations, a spokesperson responded that the “questions are based on incorrect premises”.

“This background aligns with the functions of her job,” the representative stated, noting the time Dr. Høeg spent guiding the agency head on “medication safety and regulatory science, including computational safety modeling and shot safety tracking”.

As acting director, Dr. Høeg inherits the commissioner’s controversial expedited review system, a disputed one-day therapy clearance system that reportedly troubled her predecessors. “By what process are these medications being selected for this fast-track system? Who makes the calls?” Dr. Howard said. “There’s a lot of lack of transparency going on at the regulatory body right now.”

Overall, he stated, “the FDA seems to be moving towards laxer oversight of most medications, except for vaccines.”

Public History on Immunizations

With immunizations, Dr. Høeg has a more documented, if problematic, history, critics observe. She published a research paper using unverified crowd-sourced reports to estimate the incidence of heart inflammation following COVID-19 immunization. She consulted for the Florida surgeon general Joseph Ladapo, who was said to have changed statistics to imply Covid vaccinations are riskier than they are.

Part of her “wish list” for the current government included changing rules for recently developed shots and discontinuing “unnecessary” vaccines, she stated following the vote on a podcast. At the agency, Høeg has allegedly suggested barring teenage boys from receiving Covid vaccinations.

“She is an complete dogmatist who begins with her conclusions and tailors the evidence to retrofit the data in a extremely misleading, fraudulent way,” Dr. Howard stated.

Consolidating Power and a “Campaign of Retribution”

Dr. Høeg aligned with fellow skeptics, {like|